anurajms/meta_analysis huggingface dataset:
MESH terms:
Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta‐analysis
1. Adrenergic beta-2 Receptor Antagonists [therapeutic use]; 2. Bias; 3. Esophageal and Gastric Varices [*complications, mortality]; 4. Gastrointestinal Hemorrhage [etiology, mortality, *prevention & control]; 5. Ligation [adverse effects, methods]; 6. Liver Cirrhosis [*complications]; 7. Liver Transplantation [statistics & numerical data]; 8. *Network Meta-Analysis; 9. Nitrates [therapeutic use]; 10. *Portasystemic Shunt, Transjugular Intrahepatic [statistics & numerical data]; 11. Randomized Controlled Trials as Topic; 12. Sclerotherapy [adverse effects, mortality]; 13. Secondary Prevention [*methods];
MESH terms:
Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease
1. Adrenal Cortex Hormones [adverse effects]; 2. Aminosalicylic Acids [adverse effects]; 3. Bias; 4. Colitis, Ulcerative [drug therapy]; 5. Confidence Intervals; 6. Crohn Disease [drug therapy]; 7. Immunologic Factors [adverse effects]; 8. Infections [*chemically induced, epidemiology]; 9. Inflammatory Bowel Diseases [*drug therapy]; 10. Integrins [antagonists & inhibitors]; 11. Observational Studies as Topic [statistics & numerical data]; 12. Odds Ratio; 13. Postoperative Complications [*chemically induced, epidemiology]; 14. Surgical Wound Dehiscence [chemically induced, epidemiology]; 15. Surgical Wound Infection [chemically induced, epidemiology]; 16. Time Factors; 17. Tumor Necrosis Factor-alpha [antagonists & inhibitors];
MESH terms:
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis
1. Bias; 2. Cause of Death; 3. Endoscopy [*methods]; 4. Esophageal and Gastric Varices [prevention & control, *therapy]; 5. Gastrointestinal Hemorrhage [epidemiology, prevention & control, *therapy]; 6. Hepatic Encephalopathy [epidemiology, etiology]; 7. Intention to Treat Analysis; 8. Liver Cirrhosis [*complications]; 9. Portasystemic Shunt, Surgical [adverse effects, *methods]; 10. Portasystemic Shunt, Transjugular Intrahepatic [adverse effects]; 11. Randomized Controlled Trials as Topic; 12. Secondary Prevention; 13. Splenorenal Shunt, Surgical [adverse effects];
MESH terms:
Interventions for preventing postpartum constipation
1. Constipation [*prevention & control]; 2. Defecation; 3. Dietary Fiber [adverse effects, *therapeutic use]; 4. Laxatives [adverse effects, *therapeutic use]; 5. Perineum [injuries]; 6. Postpartum Period; 7. Puerperal Disorders [*prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Time Factors;
MESH terms:
Adalimumab for maintenance of remission in Crohn's disease
1. Adalimumab [adverse effects, *therapeutic use]; 2. Anti-Inflammatory Agents [adverse effects, *therapeutic use]; 3. Azathioprine [therapeutic use]; 4. Crohn Disease [*drug therapy]; 5. Drug Administration Schedule; 6. Immunosuppressive Agents [therapeutic use]; 7. Maintenance Chemotherapy [*methods, statistics & numerical data]; 8. Mercaptopurine [therapeutic use]; 9. Mesalamine [therapeutic use]; 10. Patient Dropouts [statistics & numerical data]; 11. Placebos [therapeutic use]; 12. Randomized Controlled Trials as Topic; 13. Time Factors; 14. Treatment Outcome; 15. Tumor Necrosis Factor-alpha [antagonists & inhibitors];
MESH terms:
Antibiotic prophylaxis for prevention of postoperative wound infection in adults undergoing open elective inguinal or femoral hernia repair
1. *Antibiotic Prophylaxis; 2. Elective Surgical Procedures [adverse effects, methods]; 3. Hernia, Femoral [*surgery]; 4. Hernia, Inguinal [*surgery]; 5. Herniorrhaphy [*adverse effects, methods]; 6. Randomized Controlled Trials as Topic; 7. Surgical Mesh; 8. Surgical Wound Infection [*prevention & control];
MESH terms:
Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis
1. *Intubation, Gastrointestinal [mortality]; 2. Enteral Nutrition [*methods]; 3. Length of Stay; 4. Nutritional Status; 5. Pancreatitis [mortality, *therapy]; 6. Parenteral Nutrition; 7. Randomized Controlled Trials as Topic; 8. Treatment Outcome;
MESH terms:
Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease
1. Antibodies, Monoclonal, Humanized [*therapeutic use]; 2. Crohn Disease [*therapy]; 3. Interleukin‐12 [*antagonists & inhibitors, immunology]; 4. Interleukin‐23 [*antagonists & inhibitors, immunology]; 5. Randomized Controlled Trials as Topic; 6. Remission Induction [methods]; 7. Ustekinumab [therapeutic use];
MESH terms:
Adalimumab for induction of remission in Crohn's disease
1. Adalimumab [*therapeutic use]; 2. Antibodies, Monoclonal, Humanized [*therapeutic use]; 3. Crohn Disease [*therapy]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Remission Induction; 7. Treatment Outcome;
MESH terms:
Band ligation versus beta‐blockers for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1. Adrenergic beta-Antagonists [therapeutic use]; 2. Antifibrinolytic Agents [therapeutic use]; 3. End Stage Liver Disease [complications]; 4. Esophageal and Gastric Varices [*complications, drug therapy, surgery]; 5. Gastrointestinal Hemorrhage [etiology, *prevention & control, *surgery]; 6. Ligation [*methods]; 7. Portal Vein; 8. Primary Prevention; 9. Randomized Controlled Trials as Topic; 10. Venous Thrombosis [complications];
MESH terms:
Certolizumab pegol for induction of remission in Crohn's disease
1. Antibodies, Monoclonal, Humanized [*therapeutic use]; 2. Certolizumab Pegol [*therapeutic use]; 3. Crohn Disease [*drug therapy]; 4. Immunologic Factors [therapeutic use]; 5. Induction Chemotherapy; 6. Randomized Controlled Trials as Topic; 7. Remission Induction;
MESH terms:
Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis
1. *Ascites [etiology, therapy]; 2. *Liver Cirrhosis [complications]; 3. *Paracentesis; 4. *Plasma Substitutes [therapeutic use]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Lateral pararectal versus transrectal stoma placement for prevention of parastomal herniation
1. Anastomosis, Surgical; 2. Colostomy [adverse effects, methods]; 3. Hernia, Ventral [*etiology, *prevention & control]; 4. Ileostomy [adverse effects, methods]; 5. Prolapse; 6. Randomized Controlled Trials as Topic; 7. Rectum [*surgery]; 8. Rectus Abdominis; 9. Surgical Stomas [*adverse effects];
MESH terms:
Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
1. Antidepressive Agents [*therapeutic use]; 2. Anxiety [drug therapy]; 3. Case-Control Studies; 4. Depression [*drug therapy]; 5. Inflammatory Bowel Diseases [*psychology]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Glucocorticosteroids for people with alcoholic hepatitis
1. Glucocorticoids [adverse effects, *therapeutic use]; 2. Hepatitis, Alcoholic [*drug therapy, mortality]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic;
MESH terms:
N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication
1. *Helicobacter pylori; 2. Acetylcysteine [adverse effects, *therapeutic use]; 3. Anti‐Bacterial Agents [*therapeutic use]; 4. Chemotherapy, Adjuvant [adverse effects, methods]; 5. Helicobacter Infections [*drug therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Antibiotics for induction and maintenance of remission in Crohn's disease
1. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 2. Crohn Disease [*drug therapy]; 3. Induction Chemotherapy [*methods]; 4. Maintenance Chemotherapy [*methods]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Acetyl‐L‐carnitine for patients with hepatic encephalopathy
1. Acetylcarnitine [*therapeutic use]; 2. Ammonia [blood]; 3. Chelating Agents [*therapeutic use]; 4. Fatigue [etiology]; 5. Hepatic Encephalopathy [blood, *drug therapy, etiology]; 6. Liver Cirrhosis [complications]; 7. Mental Fatigue [etiology]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic;
MESH terms:
Cannabis for the treatment of ulcerative colitis
1. *Phytotherapy [adverse effects]; 2. Cannabidiol [adverse effects, *therapeutic use]; 3. Capsules; 4. Colitis, Ulcerative [*drug therapy]; 5. Dronabinol [adverse effects, *therapeutic use]; 6. Marijuana Smoking; 7. Medical Marijuana [adverse effects, *therapeutic use]; 8. Patient Dropouts [statistics & numerical data]; 9. Placebos [therapeutic use]; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; 12. Remission Induction;
MESH terms:
Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis
1. *Portasystemic Shunt, Surgical [adverse effects, mortality]; 2. *Portasystemic Shunt, Transjugular Intrahepatic [adverse effects, mortality]; 3. Cause of Death; 4. Esophageal and Gastric Varices [complications, mortality, *surgery]; 5. Gastrointestinal Hemorrhage [etiology, mortality, *surgery]; 6. Hepatic Encephalopathy [epidemiology]; 7. Liver Cirrhosis [*complications, mortality]; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Reoperation [statistics & numerical data]; 11. Time Factors;
MESH terms:
Swallowing therapy for dysphagia in acute and subacute stroke
1. *Stroke Rehabilitation; 2. Acupuncture Therapy [statistics & numerical data]; 3. Acute Disease; 4. Deglutition; 5. Deglutition Disorders [*etiology, mortality, *rehabilitation]; 6. Electric Stimulation Therapy [statistics & numerical data]; 7. Gastrostomy; 8. Intubation, Gastrointestinal; 9. Length of Stay [statistics & numerical data]; 10. Lisinopril [therapeutic use]; 11. Metoclopramide [therapeutic use]; 12. Nifedipine [therapeutic use]; 13. Physical Stimulation [methods]; 14. Pneumonia [epidemiology]; 15. Randomized Controlled Trials as Topic; 16. Stroke [*complications, mortality]; 17. Time Factors; 18. Transcranial Direct Current Stimulation [statistics & numerical data];
MESH terms:
Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices
1. Adrenergic beta‐Antagonists [adverse effects, *therapeutic use]; 2. Carvedilol [adverse effects, *therapeutic use]; 3. Esophageal and Gastric Varices [complications, *drug therapy, mortality]; 4. Gastrointestinal Hemorrhage [mortality, *prevention & control]; 5. Liver Cirrhosis [complications, *drug therapy, mortality]; 6. Nadolol [adverse effects, *therapeutic use]; 7. Primary Prevention; 8. Propranolol [adverse effects, *therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Secondary Prevention;
MESH terms:
Prokinetics for functional dyspepsia
1. Benzamides [adverse effects, therapeutic use]; 2. Benzyl Compounds [therapeutic use]; 3. Cisapride [adverse effects, therapeutic use]; 4. Domperidone [adverse effects, therapeutic use]; 5. Dyspepsia [*drug therapy]; 6. Erythromycin [analogs & derivatives, therapeutic use]; 7. Gastrointestinal Agents [adverse effects, *therapeutic use]; 8. Indoles [therapeutic use]; 9. Morpholines [therapeutic use]; 10. Numbers Needed To Treat; 11. Quality of Life; 12. Randomized Controlled Trials as Topic; 13. Thiazoles [adverse effects, therapeutic use];
MESH terms:
Modifying the consistency of food and fluids for swallowing difficulties in dementia
1. *Food Handling; 2. *Food Quality; 3. Beverages [*standards]; 4. Deglutition [*physiology]; 5. Deglutition Disorders [complications, *physiopathology]; 6. Dehydration [etiology, prevention & control]; 7. Dementia [complications, *physiopathology]; 8. Fluoroscopy [methods]; 9. Malnutrition [etiology, prevention & control]; 10. Pneumonia, Aspiration [*prevention & control]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Mesh versus non‐mesh for inguinal and femoral hernia repair
1. *Surgical Mesh [adverse effects]; 2. Activities of Daily Living; 3. Hernia, Femoral [*surgery]; 4. Hernia, Inguinal [*surgery]; 5. Herniorrhaphy [adverse effects, *methods]; 6. Length of Stay; 7. Operative Time; 8. Postoperative Complications [*etiology]; 9. Randomized Controlled Trials as Topic; 10. Secondary Prevention;
MESH terms:
Epidural analgesia versus patient‐controlled intravenous analgesia for pain following intra‐abdominal surgery in adults
1. *Analgesia, Epidural [adverse effects, mortality]; 2. *Analgesia, Patient‐Controlled [adverse effects, mortality]; 3. Analgesics, Opioid [therapeutic use]; 4. Pain Measurement; 5. Pain, Postoperative [*drug therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Surgical portosystemic shunts versus devascularisation procedures for prevention of variceal rebleeding in people with hepatosplenic schistosomiasis
1. Brain Diseases [etiology]; 2. Esophageal and Gastric Varices [complications, mortality, *surgery]; 3. Esophagus [*blood supply]; 4. Gastrointestinal Hemorrhage [etiology, mortality, *prevention & control]; 5. Liver Diseases, Parasitic [*complications]; 6. Portasystemic Shunt, Surgical [adverse effects]; 7. Postoperative Complications [etiology]; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Reoperation [statistics & numerical data]; 11. Secondary Prevention; 12. Splenectomy; 13. Splenic Diseases [*complications]; 14. Splenorenal Shunt, Surgical; 15. Stomach [*blood supply]; 16. Vascular Surgical Procedures [*methods, mortality];
MESH terms:
Prosthetic mesh placement for the prevention of parastomal herniation
1. *Surgical Mesh [adverse effects]; 2. Hernia, Abdominal [epidemiology, *prevention & control]; 3. Incidence; 4. Length of Stay [statistics & numerical data]; 5. Patient Readmission; 6. Postoperative Complications [epidemiology, *prevention & control]; 7. Prosthesis‐Related Infections [etiology]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Reoperation [statistics & numerical data]; 11. Surgical Stomas [*adverse effects];
MESH terms:
Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomy
1. Biliary Atresia [*drug therapy, etiology, mortality]; 2. Glucocorticoids [*therapeutic use]; 3. Liver Transplantation [statistics & numerical data]; 4. Portoenterostomy, Hepatic [*adverse effects, methods, mortality]; 5. Postoperative Complications [*drug therapy, etiology, mortality]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease
1. *Withholding Treatment; 2. Azathioprine [*therapeutic use]; 3. Combined Modality Therapy [methods]; 4. Crohn Disease [complications, drug therapy, *therapy]; 5. Feasibility Studies; 6. Gastrointestinal Agents [*therapeutic use]; 7. Immunosuppressive Agents [*therapeutic use]; 8. Infliximab [*therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Recurrence; 11. Remission Induction; 12. Secondary Prevention [methods];
MESH terms:
Interventions for paracetamol (acetaminophen) overdose
1. Acetaminophen [pharmacokinetics, *poisoning]; 2. Acetylcysteine [therapeutic use]; 3. Analgesics, Non-Narcotic [pharmacokinetics, *poisoning]; 4. Antidotes [therapeutic use]; 5. Charcoal [therapeutic use]; 6. Cysteamine [therapeutic use]; 7. Dimercaprol [therapeutic use]; 8. Drug Overdose [mortality, therapy]; 9. Gastric Lavage; 10. Intestinal Absorption; 11. Liver Failure, Acute [chemically induced, epidemiology, surgery]; 12. Liver Transplantation; 13. Methionine [therapeutic use]; 14. Randomized Controlled Trials as Topic;
MESH terms:
Feed thickener for infants up to six months of age with gastro‐oesophageal reflux
1. Esophageal pH Monitoring; 2. Food Additives [*therapeutic use]; 3. Gastroesophageal Reflux [epidemiology, *therapy]; 4. Infant Formula; 5. Randomized Controlled Trials as Topic;
MESH terms:
Laparoscopic versus open resection for sigmoid diverticulitis
1. Acute Disease; 2. Diverticulitis [*surgery]; 3. Laparoscopy [adverse effects, *methods, mortality]; 4. Length of Stay; 5. Postoperative Complications [epidemiology, mortality]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Reoperation [statistics & numerical data]; 9. Sigmoid Diseases [*surgery];
MESH terms:
Proton pump inhibitors for functional dyspepsia
1. Dyspepsia [*drug therapy]; 2. Histamine H2 Antagonists [therapeutic use]; 3. Proton Pump Inhibitors [adverse effects, *therapeutic use]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic;
MESH terms:
Closure methods of the appendix stump for complications during laparoscopic appendectomy
1. *Abdominal Wound Closure Techniques [adverse effects, instrumentation]; 2. Appendectomy [*adverse effects]; 3. Appendix [*surgery]; 4. Intraoperative Complications [epidemiology, prevention & control]; 5. Laparoscopy; 6. Length of Stay; 7. Operative Time; 8. Postoperative Complications [epidemiology, prevention & control]; 9. Randomized Controlled Trials as Topic; 10. Surgical Instruments [adverse effects]; 11. Surgical Staplers [adverse effects]; 12. Sutures [adverse effects];
MESH terms:
Mesalamine (5‐ASA) for the prevention of recurrent diverticulitis
1. *Secondary Prevention; 2. Anti‐Inflammatory Agents, Non‐Steroidal [adverse effects, *therapeutic use]; 3. Diverticulitis, Colonic [*prevention & control]; 4. Mesalamine [adverse effects, *therapeutic use]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
1. *Needle‐Exchange Programs; 2. *Opiate Substitution Treatment [methods]; 3. Hepatitis C [epidemiology, *prevention & control, transmission]; 4. Program Evaluation; 5. Substance Abuse, Intravenous [*complications];
MESH terms:
Direct‐acting antivirals for chronic hepatitis C
1. Antiviral Agents [adverse effects, *therapeutic use]; 2. Cause of Death; 3. Hepacivirus [drug effects]; 4. Hepatitis C, Chronic [complications, *drug therapy, mortality]; 5. Nucleic Acid Synthesis Inhibitors [adverse effects, therapeutic use]; 6. Placebos [therapeutic use]; 7. Protease Inhibitors [adverse effects, therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Safety‐Based Drug Withdrawals; 10. Simeprevir [adverse effects, therapeutic use];
MESH terms:
Ursodeoxycholic acid for cystic fibrosis‐related liver disease
1. Bile [metabolism]; 2. Cholagogues and Choleretics [*therapeutic use]; 3. Chronic Disease; 4. Cystic Fibrosis [*complications]; 5. Liver [enzymology]; 6. Liver Diseases [etiology, *prevention & control]; 7. Nutritional Status; 8. Randomized Controlled Trials as Topic; 9. Ursodeoxycholic Acid [*therapeutic use];
MESH terms:
Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
1. Cause of Death; 2. Flumazenil [adverse effects, *therapeutic use]; 3. GABA Modulators [adverse effects, *therapeutic use]; 4. Hepatic Encephalopathy [*drug therapy, etiology, mortality]; 5. Liver Cirrhosis [*complications, mortality]; 6. Placebos [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Watchful Waiting;
MESH terms:
Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
1. Abdominal Pain [chemically induced]; 2. Albumins [therapeutic use]; 3. Diarrhea [chemically induced]; 4. Hepatorenal Syndrome [classification, *drug therapy, mortality]; 5. Lypressin [adverse effects, *analogs & derivatives, therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Terlipressin; 8. Vasoconstrictor Agents [adverse effects, *therapeutic use];
MESH terms:
Management for intussusception in children
1. Air; 2. Dexamethasone [*therapeutic use]; 3. Enema [*methods]; 4. Gastrointestinal Agents [*therapeutic use]; 5. Glucagon [*therapeutic use]; 6. Glucocorticoids [*therapeutic use]; 7. Intestinal Perforation [etiology]; 8. Intussusception [surgery, *therapy]; 9. Postoperative Complications; 10. Randomized Controlled Trials as Topic; 11. Recurrence; 12. Secondary Prevention [methods];
MESH terms:
Oral calorie supplements for cystic fibrosis
1. Administration, Oral; 2. Child Nutrition Disorders [*diet therapy, etiology]; 3. Cystic Fibrosis [*complications]; 4. *Dietary Supplements [adverse effects]; 5. *Energy Intake; 6. Randomized Controlled Trials as Topic;
MESH terms:
Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
1. *Antibiotic Prophylaxis; 2. Administration, Intranasal; 3. Administration, Topical; 4. Anti‐Bacterial Agents [administration & dosage, *therapeutic use]; 5. Anti‐Infective Agents, Local [administration & dosage, therapeutic use]; 6. Antifungal Agents [administration & dosage, therapeutic use]; 7. Catheter‐Related Infections [epidemiology, *prevention & control]; 8. Device Removal [adverse effects]; 9. Injections, Intravenous; 10. Mupirocin [administration & dosage, therapeutic use]; 11. Mycoses [prevention & control]; 12. Peritoneal Dialysis [*adverse effects]; 13. Peritonitis [epidemiology, *prevention & control]; 14. Randomized Controlled Trials as Topic; 15. Vancomycin [administration & dosage, therapeutic use];
MESH terms:
Maintenance immunosuppression for adults undergoing liver transplantation: a network meta‐analysis
1. *Liver Transplantation [mortality]; 2. *Network Meta‐Analysis; 3. Azathioprine [adverse effects, therapeutic use]; 4. Bayes Theorem; 5. Cyclosporine [adverse effects, therapeutic use]; 6. Drug Therapy, Combination [mortality]; 7. Everolimus [adverse effects, therapeutic use]; 8. Glucocorticoids [adverse effects, therapeutic use]; 9. Immunosuppression Therapy [adverse effects, *methods, mortality]; 10. Immunosuppressive Agents [adverse effects, *therapeutic use]; 11. Mycophenolic Acid [adverse effects, therapeutic use]; 12. Odds Ratio; 13. Retreatment [statistics & numerical data]; 14. Sirolimus [adverse effects, therapeutic use]; 15. Tacrolimus [adverse effects, therapeutic use]; 16. Transplantation Immunology;
MESH terms:
Deprescribing versus continuation of chronic proton pump inhibitor use in adults
1. *Deprescriptions; 2. Esophagitis [*drug therapy]; 3. Gastroesophageal Reflux [*drug therapy]; 4. Inappropriate Prescribing; 5. Patient Satisfaction [statistics & numerical data]; 6. Proton Pump Inhibitors [adverse effects, *therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Withholding Treatment;
MESH terms:
Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults
1. *Clostridioides difficile; 2. Aminoglycosides [therapeutic use]; 3. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 4. Bacitracin [therapeutic use]; 5. Diarrhea [chemically induced, *drug therapy, microbiology]; 6. Enterocolitis, Pseudomembranous [complications, *drug therapy]; 7. Fidaxomicin; 8. Metronidazole [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Teicoplanin [therapeutic use]; 11. Treatment Outcome; 12. Vancomycin [therapeutic use];
MESH terms:
Hepatitis B immunoglobulin during pregnancy for prevention of mother‐to‐child transmission of hepatitis B virus
1. *Hepatitis B virus [genetics, immunology]; 2. DNA, Viral [blood]; 3. Hepatitis B [blood, *transmission]; 4. Hepatitis B Surface Antigens [blood]; 5. Hepatitis B e Antigens [blood]; 6. Immunization, Passive [*methods]; 7. Immunoglobulins [*administration & dosage]; 8. Infectious Disease Transmission, Vertical [prevention & control]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Mesh fixation with glue versus suture for chronic pain and recurrence in Lichtenstein inguinal hernioplasty
1. Chronic Pain [*prevention & control]; 2. *Fibrin Tissue Adhesive; 3. Herniorrhaphy [*methods]; 4. Pain, Postoperative [*prevention & control]; 5. Primary Prevention [methods]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. *Surgical Mesh; 9. Surgical Wound Infection [epidemiology]; 10. *Sutures;
MESH terms:
Polymer‐based oral rehydration solution for treating acute watery diarrhoea
1. Acute Disease; 2. Cholera [complications]; 3. Dehydration [etiology, *therapy]; 4. Diarrhea [complications, *therapy]; 5. Fluid Therapy [*methods]; 6. Oryza; 7. Polymers [*therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Rehydration Solutions [chemistry, *therapeutic use];
MESH terms:
Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease
1. Antibodies, Monoclonal [administration & dosage, *therapeutic use]; 2. Antibodies, Monoclonal, Humanized [administration & dosage, *therapeutic use]; 3. Crohn Disease [*therapy]; 4. Injections, Intravenous; 5. Interleukin‐12 [*antagonists & inhibitors, immunology]; 6. Interleukin‐23 [*antagonists & inhibitors, immunology]; 7. Randomized Controlled Trials as Topic; 8. Remission Induction [methods]; 9. Ustekinumab [administration & dosage, *therapeutic use];
MESH terms:
Methods to decrease blood loss during liver resection: a network meta‐analysis
1. Bayes Theorem; 2. Blood Loss, Surgical [*prevention & control]; 3. Blood Transfusion [statistics & numerical data]; 4. Catheter Ablation [methods]; 5. Fibrin Tissue Adhesive [administration & dosage]; 6. Hemostasis, Surgical [*methods]; 7. Hepatectomy [adverse effects, *methods]; 8. Randomized Controlled Trials as Topic; 9. Suction [instrumentation, methods];
MESH terms:
Heated insufflation with or without humidification for laparoscopic abdominal surgery
1. *Carbon Dioxide; 2. Analgesics, Opioid [administration & dosage]; 3. Body Temperature; 4. Hot Temperature [*therapeutic use]; 5. Humidity; 6. Hypothermia [*prevention & control]; 7. Insufflation [*methods]; 8. Intraoperative Complications [*prevention & control]; 9. Laparoscopy [methods]; 10. Morphine [administration & dosage]; 11. Pain, Postoperative [prevention & control]; 12. Pneumoperitoneum, Artificial [methods]; 13. Randomized Controlled Trials as Topic;
MESH terms:
Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease
1. Administration, Oral; 2. Anti‐Inflammatory Agents, Non‐Steroidal [*administration & dosage]; 3. Crohn Disease [*prevention & control]; 4. Mesalamine [*administration & dosage]; 5. Remission Induction; 6. Secondary Prevention; 7. Sulfasalazine [administration & dosage];
MESH terms:
Internal dressings for healing perianal abscess cavities
1. *Bandages; 2. *Wound Healing; 3. Abscess [*surgery]; 4. Anus Diseases [etiology, *therapy]; 5. Drainage; 6. Postoperative Complications [*therapy]; 7. Randomized Controlled Trials as Topic; 8. Rectal Fistula [etiology, *therapy]; 9. Self Care; 10. Time Factors;
MESH terms:
Osmotic and stimulant laxatives for the management of childhood constipation
1. Constipation [*drug therapy]; 2. Defecation [drug effects]; 3. Dietary Fiber [adverse effects, therapeutic use]; 4. Enema; 5. Lactulose [adverse effects, therapeutic use]; 6. Laxatives [adverse effects, *therapeutic use]; 7. Magnesium Hydroxide [adverse effects, therapeutic use]; 8. Mineral Oil [adverse effects, therapeutic use]; 9. Osmosis; 10. Polyethylene Glycols [adverse effects, *therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Senna Extract [adverse effects, therapeutic use]; 13. Sennosides; 14. Treatment Outcome;
MESH terms:
Anti‐tuberculous therapy for maintenance of remission in Crohn's disease
1. *Secondary Prevention; 2. Antitubercular Agents [adverse effects, *therapeutic use]; 3. Clarithromycin [therapeutic use]; 4. Clofazimine [therapeutic use]; 5. Crohn Disease [drug therapy, *prevention & control]; 6. Ethambutol [therapeutic use]; 7. Glucocorticoids [therapeutic use]; 8. Maintenance Chemotherapy [*methods]; 9. Methylprednisolone [therapeutic use]; 10. Prednisone [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Recurrence; 13. Remission Induction; 14. Rifabutin [therapeutic use]; 15. Rifampin [therapeutic use];
MESH terms:
Epidural local anaesthetics versus opioid‐based analgesic regimens for postoperative gastrointestinal paralysis, vomiting and pain after abdominal surgery
1. *Anesthesia, Epidural; 2. Abdomen [*surgery]; 3. Analgesics, Opioid [*therapeutic use]; 4. Anesthetics, Local [*therapeutic use]; 5. Flatulence; 6. Gastrointestinal Diseases [drug therapy, etiology]; 7. Gastrointestinal Transit [drug effects]; 8. Pain, Postoperative [drug therapy]; 9. Paralysis [drug therapy, etiology]; 10. Postoperative Complications [*drug therapy]; 11. Postoperative Nausea and Vomiting [drug therapy]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Aminosalicylates for induction of remission or response in Crohn's disease
1. Aminosalicylic Acids [therapeutic use]; 2. Anti‐Inflammatory Agents, Non‐Steroidal [*therapeutic use]; 3. Budesonide [therapeutic use]; 4. Crohn Disease [*drug therapy]; 5. Delayed‐Action Preparations; 6. Gastrointestinal Agents [*therapeutic use]; 7. Induction Chemotherapy [*methods]; 8. Mesalamine [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Sulfasalazine [therapeutic use];
MESH terms:
Sequential versus standard triple first‐line therapy for Helicobacter pylori eradication
1. *Helicobacter pylori; 2. Drug Therapy, Combination [methods]; 3. Geography, Medical; 4. Helicobacter Infections [*drug therapy]; 5. Intention to Treat Analysis; 6. Randomized Controlled Trials as Topic;
MESH terms:
Booster dose vaccination for preventing hepatitis B
1. Hepatitis B [immunology, *prevention & control]; 2. Hepatitis B Antibodies [immunology]; 3. Hepatitis B Surface Antigens [immunology]; 4. Hepatitis B Vaccines [*administration & dosage, immunology]; 5. *Immunization, Secondary;
MESH terms:
Fasting for haemostasis in children with gastrointestinal bleeding
1. *Fasting; 2. Gastrointestinal Hemorrhage [etiology, *therapy]; 3. *Hemostasis;
MESH terms:
Pancreatic duct guidewire placement for biliary cannulation for the prevention of post‐endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis
1. *Common Bile Duct; 2. *Pancreatic Ducts; 3. Catheterization [instrumentation, *methods]; 4. Cholangiopancreatography, Endoscopic Retrograde [*adverse effects]; 5. Pancreatitis [etiology, *prevention & control]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis
1. Disaccharides [adverse effects, *therapeutic use]; 2. Hepatic Encephalopathy [*drug therapy, mortality, *prevention & control]; 3. Lactulose [*therapeutic use]; 4. Liver Cirrhosis [*complications]; 5. Neomycin [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Sugar Alcohols [*therapeutic use]; 8. Watchful Waiting;
MESH terms:
Eradication therapy for peptic ulcer disease in Helicobacter pylori‐positive people
1. *Helicobacter pylori; 2. Anti‐Bacterial Agents [therapeutic use]; 3. Anti‐Ulcer Agents [therapeutic use]; 4. Drug Therapy, Combination; 5. Duodenal Ulcer [*drug therapy, microbiology]; 6. Helicobacter Infections [*drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Stomach Ulcer [*drug therapy, microbiology];
MESH terms:
Interventions for necrotising pancreatitis
1. *Peritoneal Lavage; 2. *Video‐Assisted Surgery [adverse effects]; 3. Necrosis [surgery]; 4. Pancreatitis, Acute Necrotizing [*therapy]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Perioperative dexmedetomidine for acute pain after abdominal surgery in adults
1. Abdomen [*surgery]; 2. Acute Pain [*drug therapy]; 3. Analgesics, Non‐Narcotic [adverse effects, *therapeutic use]; 4. Analgesics, Opioid [administration & dosage]; 5. Dexmedetomidine [adverse effects, *therapeutic use]; 6. Fentanyl [therapeutic use]; 7. Pain Measurement; 8. Pain, Postoperative [*drug therapy];
MESH terms:
Interventions for dysphagia in long‐term, progressive muscle disease
1. Chronic Disease; 2. Deglutition; 3. Deglutition Disorders [*drug therapy, etiology]; 4. Immunoglobulins, Intravenous [*therapeutic use]; 5. Immunologic Factors [*therapeutic use]; 6. Muscular Diseases [*complications, *drug therapy]; 7. Myositis, Inclusion Body [complications, drug therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Glutamine for induction of remission in Crohn's disease
1. Crohn Disease [*drug therapy]; 2. Glutamine [*therapeutic use]; 3. Induction Chemotherapy [methods]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Periodontal therapy as adjunctive treatment for gastric Helicobacter pylori infection
1. *Helicobacter pylori; 2. Helicobacter Infections [prevention & control, *therapy]; 3. Periodontics; 4. Periodontitis [*therapy]; 5. Randomized Controlled Trials as Topic; 6. Recurrence; 7. Secondary Prevention [methods];
MESH terms:
Duodenum‐preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
1. *Duodenum; 2. Length of Stay; 3. Organ Sparing Treatments [*methods]; 4. Pancreatectomy [*methods]; 5. Pancreaticoduodenectomy [*methods]; 6. Pancreatitis, Chronic [*surgery]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Pregabalin for decreasing pancreatic pain in chronic pancreatitis
1. Analgesics [*therapeutic use]; 2. Chronic Pain [*drug therapy, etiology]; 3. Pancreatic Diseases [*drug therapy, etiology]; 4. Pancreatitis, Chronic [*complications]; 5. Pregabalin [*therapeutic use]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery
1. *Clinical Protocols; 2. *Digestive System Surgical Procedures; 3. Early Ambulation; 4. Enteral Nutrition; 5. Esophagectomy; 6. Gastrectomy; 7. Length of Stay; 8. Liver [*surgery]; 9. Pain Management; 10. Pancreas [*surgery]; 11. Preoperative Care; 12. Quality of Life; 13. Randomized Controlled Trials as Topic; 14. Standard of Care;
MESH terms:
Antibiotic prophylaxis for surgical site infection in people undergoing liver transplantation
1. *Antibiotic Prophylaxis; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Ceftriaxone [*therapeutic use]; 4. Liver Transplantation [*adverse effects]; 5. Metronidazole [*therapeutic use]; 6. Surgical Wound Infection [*prevention & control];
MESH terms:
Etrolizumab for induction of remission in ulcerative colitis
1. Antibodies, Monoclonal, Humanized [administration & dosage, adverse effects, *therapeutic use]; 2. Colitis, Ulcerative [*drug therapy]; 3. Induction Chemotherapy [adverse effects, *methods]; 4. Randomized Controlled Trials as Topic; 5. Time Factors;
MESH terms:
Surgery for complete (full‐thickness) rectal prolapse in adults
1. Randomized Controlled Trials as Topic; 2. Rectal Prolapse [*surgery]; 3. Rectum [*surgery]; 4. Treatment Outcome;
MESH terms:
Treatment for dysphagia (swallowing difficulties) in hereditary ataxia
1. Deglutition Disorders [etiology, *therapy]; 2. Spinocerebellar Degenerations [*complications];
MESH terms:
Laparoscopic fundoplication surgery versus medical management for gastro‐oesophageal reflux disease (GORD) in adults
1. Fundoplication [adverse effects, *methods]; 2. Gastroesophageal Reflux [*surgery, *therapy]; 3. Health Status; 4. Heartburn [etiology]; 5. Laparoscopy; 6. Proton Pump Inhibitors [*therapeutic use]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic;
MESH terms:
Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease
1. Azathioprine [adverse effects, *therapeutic use]; 2. Crohn Disease [drug therapy, *prevention & control]; 3. Immunosuppressive Agents [*therapeutic use]; 4. Maintenance Chemotherapy [*methods]; 5. Mercaptopurine [adverse effects, *therapeutic use]; 6. Prodrugs [*therapeutic use]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Oral budesonide for induction of remission in ulcerative colitis
1. Administration, Oral; 2. Anti‐Inflammatory Agents [*administration & dosage, adverse effects]; 3. Anti‐Inflammatory Agents, Non‐Steroidal [administration & dosage]; 4. Budesonide [*administration & dosage, adverse effects]; 5. Colitis, Ulcerative [*drug therapy]; 6. Induction Chemotherapy [methods]; 7. Mesalamine [administration & dosage]; 8. Prednisone [administration & dosage]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Noninvasive positive pressure ventilation for acute respiratory failure following upper abdominal surgery
1. Abdomen [*surgery]; 2. Continuous Positive Airway Pressure [adverse effects, *methods]; 3. Length of Stay; 4. Noninvasive Ventilation [adverse effects, *methods]; 5. Oxygen Inhalation Therapy; 6. Postoperative Complications [*therapy]; 7. Randomized Controlled Trials as Topic; 8. Respiratory Distress Syndrome [etiology, *therapy];
MESH terms:
Preoperative inspiratory muscle training for postoperative pulmonary complications in adults undergoing cardiac and major abdominal surgery
1. Abdomen [*surgery]; 2. Breathing Exercises [*methods]; 3. Cardiac Surgical Procedures [*adverse effects]; 4. Cause of Death; 5. Elective Surgical Procedures; 6. Inhalation; 7. Length of Stay; 8. Pneumonia [*prevention & control]; 9. Postoperative Complications [mortality, *prevention & control]; 10. Preoperative Care [*methods]; 11. Pulmonary Atelectasis [*prevention & control]; 12. Randomized Controlled Trials as Topic; 13. Respiratory Muscles;
MESH terms:
Interventions for heartburn in pregnancy
1. *Acupuncture Therapy; 2. Aluminum Hydroxide [therapeutic use]; 3. Antacids [*therapeutic use]; 4. Heartburn [*therapy]; 5. Magnesium Hydroxide [therapeutic use]; 6. Neostigmine [therapeutic use]; 7. Pregnancy Complications [*therapy]; 8. Randomized Controlled Trials as Topic; 9. Sucralfate [therapeutic use];
MESH terms:
Type I interferons for induction of remission in ulcerative colitis
1. Anti‐Inflammatory Agents [therapeutic use]; 2. Colitis, Ulcerative [*drug therapy]; 3. Enema [methods]; 4. Induction Chemotherapy; 5. Interferon Type I [*therapeutic use]; 6. Interferon‐alpha [therapeutic use]; 7. Interferon‐beta [therapeutic use]; 8. Prednisolone [therapeutic use]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Methotrexate for maintenance of remission in ulcerative colitis
1. Administration, Oral; 2. Colitis, Ulcerative [*drug therapy]; 3. Immunosuppressive Agents [*administration & dosage]; 4. Maintenance Chemotherapy [*methods]; 5. Mercaptopurine [therapeutic use]; 6. Mesalamine [therapeutic use]; 7. Methotrexate [*administration & dosage]; 8. Sulfasalazine [therapeutic use];
MESH terms:
Unfractionated or low‐molecular weight heparin for induction of remission in ulcerative colitis
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Colitis, Ulcerative [*drug therapy]; 3. Delayed‐Action Preparations [adverse effects, therapeutic use]; 4. Heparin [adverse effects, *therapeutic use]; 5. Heparin, Low‐Molecular‐Weight [adverse effects, therapeutic use]; 6. Injections, Subcutaneous; 7. Intention to Treat Analysis; 8. Randomized Controlled Trials as Topic; 9. Remission Induction [methods];
MESH terms:
Post‐pyloric versus gastric tube feeding for preventing pneumonia and improving nutritional outcomes in critically ill adults
1. Critical Illness; 2. Duodenum; 3. Enteral Nutrition [*methods]; 4. Gastrointestinal Motility; 5. Hospital Mortality; 6. Jejunum; 7. Length of Stay; 8. Malnutrition [*therapy]; 9. *Nutritional Status; 10. Pneumonia, Aspiration [*prevention & control]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Plugs for containing faecal incontinence
1. *Tampons, Surgical; 2. Equipment Design; 3. Fecal Incontinence [*rehabilitation]; 4. Patient Dropouts [statistics & numerical data]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease
1. Acute Disease; 2. Amino Acids [*therapeutic use]; 3. Antifibrinolytic Agents [*therapeutic use]; 4. Blood Coagulation Disorders [etiology, *therapy]; 5. Chronic Disease; 6. Gastrointestinal Hemorrhage [*therapy]; 7. Liver Diseases [*complications];
MESH terms:
Budesonide for induction of remission in Crohn's disease
1. Administration, Oral; 2. Adrenal Cortex Hormones [therapeutic use]; 3. Anti‐Inflammatory Agents [*administration & dosage, adverse effects]; 4. Anti‐Inflammatory Agents, Non‐Steroidal [therapeutic use]; 5. Budesonide [*administration & dosage, adverse effects]; 6. Crohn Disease [*drug therapy]; 7. Induction Chemotherapy [*methods]; 8. Mesalamine [therapeutic use]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Water infusion versus air insufflation for colonoscopy
1. *Water [administration & dosage]; 2. Abdominal Pain [etiology, prevention & control]; 3. Adenoma [*diagnosis]; 4. Colonoscopy [adverse effects, *methods]; 5. Colorectal Neoplasms [*diagnosis]; 6. Insufflation [*methods]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension
1. Cyanoacrylates [*administration & dosage]; 2. Endoscopy; 3. Esophageal and Gastric Varices [*complications, mortality]; 4. Gastrointestinal Hemorrhage [etiology, mortality, *therapy]; 5. Hypertension, Portal [*complications, mortality]; 6. Ligation [methods]; 7. Randomized Controlled Trials as Topic; 8. Recurrence; 9. Sclerotherapy [*methods, mortality]; 10. Secondary Prevention [methods];
MESH terms:
Enteral nutrition formulations for acute pancreatitis
1. Acute Disease; 2. Dietary Fiber [therapeutic use]; 3. Dietary Supplements; 4. Enteral Nutrition [*methods, mortality]; 5. Immunotherapy [methods, mortality]; 6. Pancreatitis [mortality, *therapy]; 7. Probiotics [therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Endoscopic or surgical intervention for painful obstructive chronic pancreatitis
1. Constriction, Pathologic [complications]; 2. Endoscopy, Gastrointestinal [adverse effects, *methods]; 3. Pain [etiology, *surgery]; 4. Pain Management [*methods]; 5. Pancreatic Ducts; 6. Pancreatitis, Chronic [*surgery]; 7. Pressure [adverse effects]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Treatment for cryoglobulinemic and non‐cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection
1. Adrenal Cortex Hormones [therapeutic use]; 2. Antibodies, Monoclonal, Murine‐Derived [therapeutic use]; 3. Antiviral Agents [adverse effects, *therapeutic use]; 4. Cryoglobulinemia [*complications, drug therapy]; 5. Cyclophosphamide [therapeutic use]; 6. Hepacivirus; 7. Hepatitis C [*complications, drug therapy]; 8. Immunologic Factors [*therapeutic use]; 9. Interferon‐alpha [adverse effects, therapeutic use]; 10. Peripheral Nervous System Diseases [*drug therapy, etiology]; 11. Randomized Controlled Trials as Topic; 12. Ribavirin [adverse effects, therapeutic use]; 13. Rituximab;
MESH terms:
Tranexamic acid for upper gastrointestinal bleeding
1. Administration, Oral; 2. Aluminum Hydroxide [therapeutic use]; 3. Anti‐Ulcer Agents [therapeutic use]; 4. Antifibrinolytic Agents [adverse effects, *therapeutic use]; 5. Cimetidine [therapeutic use]; 6. Drug Combinations; 7. Endoscopy, Gastrointestinal; 8. Gastrointestinal Hemorrhage [*drug therapy, mortality]; 9. Injections, Intravenous; 10. Lansoprazole [therapeutic use]; 11. Magnesium [therapeutic use]; 12. Magnesium Hydroxide [therapeutic use]; 13. Randomized Controlled Trials as Topic; 14. Tranexamic Acid [adverse effects, *therapeutic use];
MESH terms:
Hepatitis B vaccination during pregnancy for preventing infant infection
1. *Vaccination; 2. Hepatitis B [*transmission]; 3. Hepatitis B Vaccines [*administration & dosage]; 4. Infectious Disease Transmission, Vertical [*prevention & control]; 5. Pregnancy Complications, Infectious [*prevention & control];
MESH terms:
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease
1. Anti‐Inflammatory Agents, Non‐Steroidal [adverse effects]; 2. Celecoxib; 3. Colitis, Ulcerative [complications, *drug therapy]; 4. Crohn Disease [complications, *drug therapy]; 5. Cyclooxygenase 2 Inhibitors [*adverse effects]; 6. Diclofenac [adverse effects, analogs & derivatives]; 7. Etoricoxib; 8. Isoxazoles [adverse effects]; 9. Lactones [adverse effects]; 10. Pyrazoles [*adverse effects]; 11. Pyridines [*adverse effects]; 12. Randomized Controlled Trials as Topic; 13. Safety‐Based Drug Withdrawals; 14. Sulfonamides [*adverse effects]; 15. Sulfones [*adverse effects];
MESH terms:
Non‐nutritive sucking for gastro‐oesophageal reflux disease in preterm and low birth weight infants
1. *Pacifiers; 2. Crying; 3. Gastroesophageal Reflux [*therapy]; 4. Infant, Low Birth Weight; 5. Infant, Premature; 6. Infant, Premature, Diseases [*therapy];
MESH terms:
Epinephrine injection versus epinephrine injection and a second endoscopic method in high‐risk bleeding ulcers
1. Combined Modality Therapy [methods]; 2. Epinephrine [*administration & dosage]; 3. Hemostasis, Endoscopic [*methods]; 4. Peptic Ulcer Hemorrhage [mortality, prevention & control, *therapy]; 5. Randomized Controlled Trials as Topic; 6. Secondary Prevention [methods]; 7. Vasoconstrictor Agents [*administration & dosage];
MESH terms:
Interventions for treating postpartum constipation
1. *Postpartum Period; 2. Constipation [*therapy];
MESH terms:
Budesonide for maintenance of remission in Crohn's disease
1. Administration, Oral; 2. Anti‐Inflammatory Agents [*administration & dosage]; 3. Budesonide [*administration & dosage]; 4. Crohn Disease [*drug therapy]; 5. Induction Chemotherapy [methods]; 6. Maintenance Chemotherapy [*methods]; 7. Randomized Controlled Trials as Topic; 8. Risk; 9. Secondary Prevention;
MESH terms:
Vedolizumab for induction and maintenance of remission in ulcerative colitis
1. Antibodies, Monoclonal, Humanized [adverse effects, *therapeutic use]; 2. Colitis, Ulcerative [prevention & control, *therapy]; 3. Induction Chemotherapy [*methods]; 4. Maintenance Chemotherapy [*methods]; 5. Randomized Controlled Trials as Topic; 6. Secondary Prevention;
MESH terms:
Methotrexate for induction of remission in refractory Crohn's disease
1. Antibodies, Monoclonal [therapeutic use]; 2. Azathioprine [therapeutic use]; 3. Crohn Disease [*drug therapy]; 4. Immunosuppressive Agents [*therapeutic use]; 5. Induction Chemotherapy [*methods]; 6. Infliximab; 7. Mercaptopurine [therapeutic use]; 8. Methotrexate [*therapeutic use]; 9. Prednisone [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Steroids [therapeutic use];
MESH terms:
Antimicrobial drugs for treating cholera
1. Anti‐Bacterial Agents [therapeutic use]; 2. Anti‐Infective Agents [*therapeutic use]; 3. Cholera [*drug therapy]; 4. Diarrhea [drug therapy, microbiology]; 5. Fluid Therapy [methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Antimicrobial prophylaxis for colorectal surgery
1. *Antibiotic Prophylaxis; 2. Anti‐Infective Agents [*therapeutic use]; 3. Bacterial Infections [*prevention & control]; 4. Colon [*surgery]; 5. Randomized Controlled Trials as Topic; 6. Rectum [*surgery]; 7. Surgical Wound Infection [*prevention & control];
MESH terms:
Botulinum toxin for upper oesophageal sphincter dysfunction in neurological swallowing disorders
1. Anti‐Dyskinesia Agents [*therapeutic use]; 2. Botulinum Toxins [*therapeutic use]; 3. Deglutition [*drug effects, physiology]; 4. Deglutition Disorders [*drug therapy, etiology]; 5. Esophageal Sphincter, Upper; 6. Nervous System Diseases [complications];
MESH terms:
Dopamine agents for hepatic encephalopathy
1. Bromocriptine [*therapeutic use]; 2. Dopamine Agonists [*therapeutic use]; 3. Hepatic Encephalopathy [*drug therapy]; 4. Levodopa [*therapeutic use]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Early versus delayed laparoscopic cholecystectomy for acute gallstone pancreatitis
1. Acute Disease; 2. Cholecystectomy, Laparoscopic [*adverse effects]; 3. Gallstones [complications, *surgery]; 4. Pancreatitis [etiology, *surgery]; 5. Randomized Controlled Trials as Topic; 6. Time Factors;
MESH terms:
Abdominal lift for laparoscopic cholecystectomy
1. *Abdominal Wall; 2. Blood Pressure; 3. Cardiac Output; 4. Cholecystectomy, Laparoscopic [*methods]; 5. Combined Modality Therapy [methods]; 6. Heart Rate; 7. Lifting [*adverse effects]; 8. Lung Compliance; 9. Operative Time; 10. Pneumoperitoneum, Artificial [*adverse effects]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Opioids for acute pancreatitis pain
1. Abdominal Pain [*drug therapy, etiology]; 2. Acute Disease; 3. Analgesics, Opioid [*administration & dosage]; 4. Buprenorphine [administration & dosage]; 5. Fentanyl [administration & dosage]; 6. Meperidine [administration & dosage]; 7. Morphine [administration & dosage]; 8. Pancreatitis [*complications]; 9. Pentazocine [administration & dosage]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Laparoscopic repair for perforated peptic ulcer disease
1. *Laparoscopy; 2. Peptic Ulcer Perforation [*surgery]; 3. Randomized Controlled Trials as Topic;